Bisphosphonate Therapy in Multiple Myeloma in Preventing Vertebral Collapses: Preliminary Report

Overview

Journal Eur Spine J

Specialty Orthopedics

Date 2012 Mar 22

PMID 22434531

Citations 5

Authors

Francesco C Tamburrelli

L Proietti

L Scaramuzzo

V De Stefano

C A Logroscino

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of the study was to report and discuss the preliminary data obtained in a homogeneous series of 50 patients affected by multiple myeloma treated with bisphosphonates.

Methods: Patients were followed for a minimum of 1 year. Main orthopaedic data were recorded. Visual Analogue Score and QLQ-C30 and MY 20 were used to assess the quality of life.

Results: Statistical analysis showed less lytic lesions in the group with zoledronate therapy and stable primary disease compared with a greater number of lesions in the non-treated group. Results regarding VAS score and QLQ-C30 and MY were statistically better in the first group than in the second.

Conclusions: Our results confirm the efficacy of zoledronate in ensuring an acceptable quality of life restraining the aggressiveness of the myeloma on bone tissue, especially in spine although further prospective studies have to be conducted to determine its correct use in myeloma patients.

Citing Articles

Bisphosphonates May Reduce Intraoperative Blood Loss in Surgery for Metastatic Spinal Disease: A Retrospective Cohort Study.

Zhang H, Zhao Y, Qiao R, Li J, Hu Y Clin Interv Aging. 2021; 16:1943-1953.

PMID: 34754183 PMC: 8570722. DOI: 10.2147/CIA.S324975.

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.

Mbese Z, Aderibigbe B Int J Mol Sci. 2021; 22(13).

PMID: 34206757 PMC: 8268474. DOI: 10.3390/ijms22136869.

Vertebral lesion distribution in multiple myeloma--assessed by reduced-dose whole-body MDCT.

Bier G, Kloth C, Schabel C, Bongers M, Nikolaou K, Horger M Skeletal Radiol. 2015; 45(1):127-33.

PMID: 26476728 DOI: 10.1007/s00256-015-2268-4.

Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.

Wu J, Zheng W, Tan Y, Hu X, Huang Q, Fan K Biomed Res Int. 2015; 2015:936307.

PMID: 25685817 PMC: 4317594. DOI: 10.1155/2015/936307.

Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid.

Kmetec A, Hajdinjak T Radiol Oncol. 2013; 47(3):289-95.

PMID: 24133394 PMC: 3794885. DOI: 10.2478/raon-2013-0041.

References

Body J, Mancini I . Bisphosphonates for cancer patients: why, how, and when?. Support Care Cancer. 2002; 10(5):399-407. DOI: 10.1007/s005200100292. View

Terpos E, Dimopoulos M . Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005; 16(8):1223-31. DOI: 10.1093/annonc/mdi235. View

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

Knop C, Oeser M, Bastian L, Lange U, Zdichavsky M, Blauth M . [Development and validation of the Visual Analogue Scale (VAS) Spine Score]. Unfallchirurg. 2001; 104(6):488-97. DOI: 10.1007/s001130170111. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

Lacerna L, Hohneker J . Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol. 2003; 30(5 Suppl 16):150-60. DOI: 10.1053/j.seminoncol.2003.08.017. View

Hirsh V, Tchekmedyian N, Rosen L, Zheng M, Hei Y . Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004; 6(3):170-4. DOI: 10.3816/CLC.2004.n.030. View

Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H . Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002; (3):CD003188. DOI: 10.1002/14651858.CD003188. View

Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P . Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 2000; 14(12):2048-56. DOI: 10.1359/jbmr.1999.14.12.2048. View

10.

Sabino M, Mantyh P . Pathophysiology of bone cancer pain. J Support Oncol. 2005; 3(1):15-24. View

11.

Yeh H, Berenson J . Treatment for myeloma bone disease. Clin Cancer Res. 2006; 12(20 Pt 2):6279s-6284s. DOI: 10.1158/1078-0432.CCR-06-0681. View

12.

. Diagnosis and management of multiple myeloma. Br J Haematol. 2001; 115(3):522-40. DOI: 10.1046/j.1365-2141.2001.03206.x. View

13.

Hansen-Algenstaedt N, Joscheck C, Wolfram L, Schaefer C, Muller I, Bottcher A . Sequential changes in vessel formation and micro-vascular function during bone repair. Acta Orthop. 2006; 77(3):429-39. DOI: 10.1080/17453670610046361. View

14.

Terpos E, Sezer O, Croucher P, Garcia-Sanz R, Boccadoro M, San Miguel J . The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009; 20(8):1303-17. DOI: 10.1093/annonc/mdn796. View

15.

Croucher P, De Hendrik R, Perry M, Hijzen A, Shipman C, Lippitt J . Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003; 18(3):482-92. DOI: 10.1359/jbmr.2003.18.3.482. View

16.

Silvestris F, Cafforio P, Calvani N, Dammacco F . Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol. 2004; 126(4):475-86. DOI: 10.1111/j.1365-2141.2004.05084.x. View

17.

Gordon S, Helfrich M, Sati H, Greaves M, Ralston S, Culligan D . Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol. 2002; 119(2):475-83. DOI: 10.1046/j.1365-2141.2002.03824.x. View

18.

Costa L, Major P . Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009; 6(3):163-74. DOI: 10.1038/ncponc1323. View

19.

Mundy G, Bertolini D . Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 1986; 13(3):291-9. View

20.

Licata A . Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005; 39(4):668-77. DOI: 10.1345/aph.1E357. View